Abstract-Treatment of the protected ribose or xylose 5-aldehyde with sulfonyl-stabilized fluorophosphonate gave (fluoro)vinyl sulfones. Stannyldesulfonylation followed by iododestannylation afforded 5,6-dideoxy-6-fluoro-6-iodo-D D-ribo or xylo-hex-5-enofuranoses. Coupling of the hexenofuranoses with alkylzinc bromides gave 10-carbon ribosyl-and xylosylhomocysteine analogues incorporating a fluoroalkene. The fluoroalkenyl and alkenyl analogues were evaluated for inhibition of Bacillus subtilis S-ribosylhomocysteinase (LuxS). One of the compounds, 3,5,6-trideoxy-6-fluoro-D D-erythro-hex-5-enofuranose, acted as a competitive inhibitor of moderate potency (K I = 96 lM).
Introduction
S-Adenosyl-L L-homocysteine (SAH) is a byproduct of many methyltransferase reactions and a potent inhibitor of the methyltransferases. In eukaryotes and some bacteria, detoxification of SAH is mediated by SAH hydrolase (EC 3.3.1.1) , which effects hydrolytic cleavage of SAH to L L-homocysteine (Hcy) and adenosine ( Fig. 1) . 1 Hcy appears to be a risk factor for coronary artery diseases. 2 Alternatively, most bacteria utilize enzyme 5 0 -methylthioadenosine (MTA)/SAH nucleosidase (EC 3.2.2.9) to irreversibly cleave SAH yielding adenine and S-ribosyl-L L-homocysteine (SRH). 3 The SRH is then converted to Hcy and 2,4-dihydroxy-2,3-pentadione (DPD) by a metalloenzyme S-ribosylhomocysteinase (LuxS). 4 DPD 5 spontaneously cyclizes and complexes with borate to form a furanosyl borate diester, which acts as a type 2 autoinducer for bacterial interspecies quorum sensing.
6
Since quorum sensing regulates many bacterial behaviors such as virulence and biofilm formation, LuxS and other proteins involved in quorum sensing have been proposed as attractive targets for novel antibacterial drug design.
7
Several substrate analogues of SRH (e.g., 1 and 2) showed submicromolar inhibition of LuxS.
4e,h
We have previously observed that SAH hydrolase is capable of the addition of water across 5 0 ,6 0 isolated double bond of adenosine analogues 3 and 4 (Fig. 2) . 1c,8 The resulting adduct (or its derivative) caused covalent modification and inactivation 8b of the enzyme, a process which required the catalytic activity of the enzyme. Since LuxS catalyzes a similar reaction as SAH hydrolase (i.e., overall elimination of Hcy), we designed analogues of SRH with the vinyl or halovinyl moieties incorporated in place of the carbon-5 and sulfur atoms (e.g., 5). We envisaged that these ribosyl analogues might serve as mechanistic probes to study the mechanism of action of LuxS and evaluate the similarities between SAH hydrolase and LuxS. As mentioned above, LuxS inhibitors may provide a novel class of antibacterial agents. We now describe the syntheses of SRH analogues with the carbon-5 and sulfur atoms replaced by vinyl or (6-fluoro)vinyl motifs and discuss their interactions with LuxS enzyme.
Chemistry
Our initial plan to prepare compound 5 and its congeners is illustrated in Scheme 1. Treatment of the diacetone 3-O-benzoylglucose 6 or allose 7 with periodic acid selectively removed the 5,6-O-isopropylidene group. Subsequent oxidative cleavage of the exposed vicinal diol 9a gave the corresponding 5-aldehydes 8 and 9, respectively, in high yields (Scheme 1). Wittig olefination of aldehyde 8 with the ylide derived from commercially available [4-ethoxy-4-oxobutyltriphenylphoshonium bromide provided a complex mixture of products. Column chromatography yielded protected 5,6,7, 8-tetradeoxy-a-D D-xylo-non-5(Z)-enofuranuronate 10 (18% yield). The stereochemistry was assigned as Z, based on the magnitude of the coupling constants for olefinic protons ( 3 J 5-6 = 11. 1 Hz) , and literature precedence for the Wittig condensations of aliphatic aldehydes with the non-stabilized ylides.
9b Similarly, Wittig-treatment of ribo 5-aldehyde 9 gave 11; a nine-carbon analogue of SRH. Unfortunately, our attempts to add bromine (CH 2 Cl 2 /0°C) across the double bond of 10 or 11 (as well as 16) produced a complex mixture which did not give the desired SRH analogues of type 5 bearing a (6-bromo)vinyl unit when treated with DBU. 10 In an alternative approach, we attempted a synthesis of 6-bromoalkenyl analogues 5 (X = Br) via Pd-catalyzed monoalkylation [11] [12] [13] of the readily available (gem-dibromo)vinyl sugar precursors (e.g., 12 and 13) with the corresponding alkylzinc reagents. Thus, dibromolefination of xylo 5-aldehyde 8 by the Corey-Fuchs procedure 14 gave 5-(dibromomethylene)-5-deoxyxylose 12 (81% from 6; Scheme 2). Analogous treatment of the ribo 5-aldehyde 9 afforded 13.
15 Treatment of 12 with 3 equiv of 4-ethoxy-4-oxobutylzinc bromide in the presence of Pd(PPh 3 ) 4 at 55°C gave monoalkylated 5, 6, 7, 8, 9 -pentadeoxy-a-D D-xylo-dec-5(E)-enofuranuronate 14 (18%, [3] [4] [5] [6] and dialkylated 18 (48%) products, but did not yield the desired 6-bromoalkenyl product 15. Analogous Negishi coupling of 5-(dibromomethylene)-5-deoxyribose 13 afforded only dialkylated product 19 (54%). Changing catalyst [(Pd 2 (dba) 3 )], solvent (THF), reaction temperature (rt to 60°C) as well as adding additives (CuI, tricyclohexylphosphine) did not lead to the formation of 15 or 17 but instead produced dialkylated byproducts 18 and 19 (3-49%) in agreement with a recent report. We next explored stereoselective coupling of the gemdihalovinyl sugars containing two different halogens. We chose 5-deoxy-5-(fluoroiodomethylene) hexenofuranoses 26 and 27 because the iodo and fluoro substituents are known to have quite different reactivity towards oxidative-addition in Pd-mediated couplings. Figure 1 . Reaction pathways for SAH detoxification in eukaryotes (a) and the majority of bacteria (b). The latter is also utilized by the bacteria to produce the type 2 autoinducer. 4e,h 5 0 -Deoxy-5 0 -(halomethylene)adenosine analogues (3 and 4) which serve as suicide substrates for SAH hydrolase 8 and targeted SRH analogues (5) in which the sulfur and C5 atoms are replaced by a vinyl unit. gave (fluoro)vinyl sulfones 20 (E/Z, 7:3; 76%; Scheme 3). The stereoselective radical-mediated stannyldesulfonylation of 20 with Bu 3 SnH produced (fluoro)vinyl stannanes 23 (E/Z, 7:3; 95%). Iododestannylation of 23 with The 5,6-dideoxy-6-fluorohex-5-enofuranoses 42 and 43, depurinated analogues of 3 (X = F), were synthesized by protiodestannylation of the (fluoro)vinyl stannanes 23 and 24. Thus, treatment of 23 (E/Z, 7:3) with NH 3 / MeOH at 25°C resulted in the removal of 3-O-benzoyl group to give 36 (Scheme 5). However, prolonged heating of 36 (or 23) with NH 3 /MeOH at 65°C for 48 h effected protiodestannylation to yield a separatable mixture of (E)-39 (29%) and (Z)-39 (48%). Treatment of (E)-39 with TFA/H 2 O at 0°C gave (E)-42 (a/b, $1:1). Analogous debenzoylation and protiodestannylation of 24 (E/Z, 1:1) with NH 3 /MeOH yielded (E)-40 (32%) and (Z)-40 (26%). Acid-catalyzed removal of the isopropylidene group in (E)-40 gave 5,6-dideoxy-6-fluoro-D D-ribo-hex-5-enofuranose (E)-43 (67%; a/b, $1:4). Alternatively, concomitant protiodestannylation and removal of acetone unit in 36 or 37 with TFA also afforded 42 and 43.
The 3,5,6-trideoxy 6-fluorohex-5-enofuranose 44, which lacks a hydroxyl group at C3 and therefore cannot participate in the second enolization step of the LuxS-catalyzed reaction, 4b was also prepared. Thus, oxidation of the diacetone 3-deoxyglucose 22 with H 5 IO 6 9a and in situ treatment of the rather unstable 3-deoxyribose 5-aldehyde with the enolate generated from the sulfonyl-stabilized fluorophosphonate natively, treatment of vinyl stannanes 38 with TFA effected simultaneous protiodestannylation and removal of the acetone unit to give 44 (23% from 35; E/Z, $1:3, a/b $1:4).
Inhibition of LuxS
The (6-fluoro)vinyl xylo-(42) and ribo-hexofuranoses (43) and their 3-deoxy analogue 44 as well as (6-fluoro)vinyl xylo-and ribo-decofuranoses (33 and 34) were evaluated 4h as potential inhibitors of Bacillus subtilis S-ribosylhomocysteinase (LuxS). Compound 44 exhibited competitive inhibition of moderate potency, with a K I value of 96 ± 3 lM (Fig. 3) . None of the other compounds showed significant inhibition under the assay conditions.
Summary and conclusions
We have developed synthesis of six-, nine-, and 10-carbon analogues of ribosyl-and xylosylhomocysteines in which the carbon-5 and sulfur atoms are replaced by a vinyl or (fluoro)vinyl unit. These fluoroalkenyl and alkenyl analogues of SRH were synthesized employing either the Wittig reaction or Pd-catalyzed coupling routes. They were evaluated against B. subtilis S-ribosylhomocysteinase (LuxS). Only 3,5,6-trideoxy-6-fluoro-D D-erythro-hex-5-enofuranose acted as competitive inhibitor of moderate potency with K I = 96 lM. (10) Step (a). H 5 IO 6 (150 mg, 0.66 mmol) was added to a stirred solution of 6 (200 mg, 0.55 mmol) in dried EtOAc at ambient temperature. A precipitate appeared within the first 5 min and the resulting solution was stirred for 90 min. The precipitate was filtered off and was washed with EtOAc (2· 5 mL). The combined organic layer was washed with NaHCO 3 /H 2 O (10 mL), NaCl/ H 2 O (10 mL), dried (Na 2 SO 4 ), and evaporated to 0.69 mmol) in anhydrous THF (4 mL) in a flame-dried flask under N 2 at ambient temperature. After 15 min, a solution of the crude, preferentially freshly prepared, aldehyde 8 (160 mg of the material from Step (a)) in THF (2 mL) was added via syringe and stirring was continued overnight. EtOAc (30 mL) and NaHCO 3 /H 2 O (10 mL) were added and the separated organic was washed with NaCl/H 2 O (10 mL), dried (Na 2 SO 4 ), and evaporated. Column chromatography (10 ! 30% hexanes/EtOAc) gave 10 (39 mg, 18%) as an oil:
1 H NMR d 1.24 (t, J = 7.2 Hz, 3, CH 3 ), 1.37 and 1.62 (2· s, 2 · 3, 2· CH 3 ), 2.41 (t, J 8-7/7 0 = 6.9 Hz, 2, H8/ 8 
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Step ( (14) and
Pd[P(Ph) 3 ] 4 (22 mg, 0.014 mmol) was added to a stirred solution of 12 (42 mg, 0.094 mmol) in anhydrous benzene (3 mL) in a flame-dried flask under N 2 at ambient temperature. After 2 min, 4-ethoxy-4-oxobutylzinc bromide (0.5 M/THF; 0.56 mL, 129 mg, 0.28 mmol) was added and the resulting mixture was heated at 55°C for 6 h. The reaction mixture was cooled down to ambient temperature and was partitioned between EtOAc (30 mL) and NaHCO 3 /H 2 O (10 mL). The separated organic layer was washed with H 2 O (10 mL), NaCl/H 2 O (10 mL), dried (Na 2 SO 4 ), and evaporated. Column chromatography (10 ! 30% EtOAc/hexanes) gave recovered 12 (7 mg, 13%), 14 (7 mg, 18%), and 18 (19 mg, 48% (260 mg, 0.84 mmol) in anhydrous THF (8 mL) in a flame-dried flask under N 2 at À78°C. After 30 min, a solution of 8 (265 mg, 0.82 mmol) in THF (4 mL) was added and stirring was continued for 1.5 h. EtOAc (30 mL) and NH 4 Cl/ H 2 O (10 mL) were added and the reaction mixture was allowed to warm to ambient temperature. The separated organic layer was washed with NaHCO 3 /H 2 O (10 mL), NaCl/H 2 O (10 mL), dried (Na 2 SO 4 ), and evaporated. Column chromatography (10 ! 30% EtOAc/hexanes) gave 20 (166 mg, 76%; E/Z, 7:3) as inseparable mixture of isomers: HRMS (AP-ESI) m/z: calcd for C 22 
(E/Z)-3-O-Benzoyl-5,6-dideoxy-6-fluoro-1,2-O-isopropylidene-6-tributylstannyl-a-D D-xylo-hex-5-enofuranose (23)
Bu 3 SnH (407 mg, 0.38 mL, 1.4 mmol) was added dropwise to a degassed solution of 20 (300 mg, 0.70 mmol; E/Z, 7:3) in anhydrous toluene (5 mL) in a flame-dried flask under N 2 at ambient temperature. After an additional 10 min of degassing with N 2 , AIBN (86 mg, 0.53 mmol) was added and the reaction mixture was refluxed at 110°C with stirring for 5 h. The volatiles were evaporated and the residue was partitioned between EtOAc (50 mL) and NaHCO 3 /H 2 O (30 mL -benzoyl-5,6,7,8,9-pentadeoxy-6- 
Ethyl 3-O
Pd[P(Ph) 3 ] 4 (5 mg, 0.004 mmol) was added to a stirred solution of 26 (30 mg, 0.07 mmol; E/Z, 4:1) in anhydrous benzene (3 mL) under N 2 at ambient temperature. After 2 min, 4-ethoxy-4-oxobutylzinc bromide (0.5 M/ THF; 0.28 mL, 65 mg, 0.14 mmol) was added and the resulting mixture was heated at 55°C for 5 h. EtOAc (30 mL) and NaHCO 3 /H 2 O (10 mL) were added and the separated organic layer was washed with H 2 O (10 mL), NaCl/H 2 O (10 mL), dried (Na 2 SO 4 ), and then was evaporated. Column chromatography (10 ! 30% EtOAc/hexanes) gave (Z)-29 (18 mg, 61%, 76% based on the conversion of the E-isomer), (E)-29 (2 mg, 7%, 35% based on the conversion of the Z-isomer) and more polar byproduct tentatively assigned as 429.1910; found: 429.1903. 5.17. Ethyl 3-O-benzoyl-5,6,7,8,9-pentadeoxy-6- 1.90 ('quint', J 8-7/7 0 /9/9 0 = 6.9 Hz, 2, H8/8 0 ), 2.38 (t, J 9-8/8 0 = 6.9 Hz, 2, H9/9 0 ), 2.50 (dt, J 7-F = 23.0 Hz, J 7-8/8 0 = 7.3 Hz, 2, H7/7 0 ), 4.14 (q, J = 7.1 Hz, 2, CH 2 ), 4.75-4.80 (m, 2, H3/4), 4.95 (t, J 2-1/3 = 4. 0 Hz, 1, H2), 5.17 (dd, 1, H5), 5.88 (d, 1, H1), 5, Ar) 3.82-3.84 (m, 1, H3) 5.18. Methyl 5, 6, 7, 8, 
Compound ( Step ( Step ( 
Enzymatic assay
Inhibition assays were performed in a buffer containing 50 mM Hepes (pH 7.0), 150 mM NaCl, 150 lM 5,5
0 -dithio-bis-(2-nitrobenzoic acid), 23 and various concentrations of SRH (0-55 lM) and inhibitors (0-1 mM 
